UNSPSC 51343302: Edoxudine

This classification denotes an antiviral agent with the molecular formula C11H16N2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 15ZQM81Y3R, chemically known as uridine, 2-deoxy-5-ethyl- but generally known as edoxudine, which bears US NIH Compound Identifier 1814. European Medicines Agency schedules Edoxudine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06460MIG.

UNSPSC 51343302 Edoxudine, a Commodity code, shows minimal relevant recent state and local procurement activity. The code nominally identifies a specific antiviral pharmaceutical, yet the recent opportunities tagged under it involve naloxone (an opioid antagonist), generic multi-source pharmaceuticals and OTC products through cooperative purchasing, and medical/first aid supplies for emergency responders—none of which are edoxudine. State and local governments do procure pharmaceuticals and medical supplies through formal competitive processes, but the tagging mismatch here suggests this code receives little direct solicitation for its named product. The issuing bodies in the recent record span county health departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), municipal fire departments (City of Tampa), and cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving multiple states including Oregon), indicating that pharmaceutical and medical-supply procurement occurs across multiple jurisdiction types when aligned properly with the product scope.

Geographic activity appears across Florida, Texas, Minnesota, and Oregon in the recent record. Representative opportunities include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually (due July 26, 2023), the City of Tampa's IFB for 169 line items of medical and first aid supplies for the Fire Department Rescue Division with an estimated contract value of $700,000 and a due date of March 13, 2026, the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products (due March 26, 2026), and the Texas Health and Human Services Commission's RFI regarding direct-to-manufacturer prescription fulfillment capabilities (posted April 3, 2026). The code itself appears misapplied to the opportunities in the source; firms pursuing actual edoxudine sales to state and local buyers should verify proper code classification before investing in pursuit strategy.